Sign up to world leading COVID-19 antiviral drugs study - Swann

Date published: 25 January 2022

Health Minister Robin Swann has urged people in Northern Ireland to take part in a world leading study on life-saving COVID-19 antiviral drugs.

The PANORAMIC trial, run by the University of Oxford, is open to the over-50s, as well as adults with an underlying health condition, if they test positive for COVID-19. Around 4,500 participants across the UK have already signed up to the study, but thousands more are being recruited.

The Minister said: “Vaccines remain our most important defence against the effects of COVID-19, but these antivirals are vital in helping to protect the most vulnerable from serious illness and hospitalisation.

“Patients from Northern Ireland are among the thousands who have received the new drugs but at least 6,000 more participants are needed across the UK as soon as possible. This is so that expert scientists can understand more about how to deploy these life-saving treatments in the health service more widely later in the year.

“If you’re eligible, please step forward for the PANORAMIC trial and play your part in helping us to learn more about medicines which could save thousands of lives.” 

Antivirals are medicines which are swallowed as a capsule to help treat people with COVID-19 infections to reduce the risk of hospitalisations and death. Molnupiravir, which is currently being deployed through the study, has shown to reduce this for at risk, non-hospitalised adults with mild to moderate COVID-19 by 30% - potentially saving thousands of lives once the drugs are widely available in the health service. 

Anyone over the age of 50, or between 18 to 49 with an underlying health condition, can sign up to the study as soon as they receive a positive PCR or lateral flow test result. They need to be experiencing COVID-19 symptoms that began in the last five days to be eligible to enrol.

Chief Medical Officer Professor Sir Michael McBride said: “Antivirals are used after someone contracts the virus to slow it down, make symptoms less severe and complications less common. It’s so important that those vulnerable to COVID-19 have the best possible chance of staying protected against the virus and, most importantly, staying out of hospital. Antivirals can help with this. If you’re eligible for PANORAMIC please give serious consideration to taking part. This will help us decide how to use COVID-19 antiviral drugs for many years to come.”

Several local GP-led research hubs are being established to ensure people in Northern Ireland get access to this new COVID-19 treatment, and those offering to participate in the trial will help researchers find out if it reduces symptoms and protects the most vulnerable in the community from needing hospital treatment.

Professor Nigel Hart, co-lead of the primary care group of the Northern Ireland Clinical Research Network (NICRN) and Lead Investigator for PANORAMIC in Northern Ireland, said: “Although vaccines remain the first line of defence against COVID-19 we still require treatments for those who contract the virus. This study is evaluating anti-viral medications and there are already encouraging results, however we need to quickly generate further information to help inform UK wide plans for their routine prescribing. The best way to do this is in a clinical trial.”

The government, through the Antivirals Taskforce, has procured 4.98m courses of antivirals – including 2.23m courses of Molnupiravir and 2.75m courses of PF-07321332/ritonavir (also called Paxlovid).

Chief Pharmaceutical Officer Cathy Harrison said: “Antivirals are an important addition to our response to COVID-19 and we have secured access to two important products for patients in Northern Ireland. Getting people enrolled onto this study will inform how we may deploy these medicines more widely as soon as possible. It is vital for that we continue to focus on the development and evaluation of new treatments for COVID-19.”

Notes to editors: 


  1. For more information and to sign up to the trial, visit:  
  2. The two antivirals are Molnupiravir (also called Lagevrio) made by Merck, Sharp and Dohme (MSD), and PF-07321332 (also called Paxlovid) made by Pfizer, which is Pfizer’s novel antiviral taken alongside another drug, ritonavir.
  3. Based on trial data showing that Molnupiravir is safe and effective, the medicines regulator, the MHRA has recently licensed Molnupiravir for treatment of COVID-19.
  4. The national study is open to people who meet all the following criteria: 
  • Have received a PCR or lateral flow positive test for COVID-19. 
  • Feel unwell with symptoms of COVID-19 that started in the last 5 days; and 
  • Are aged 50+, or 18-49 years old with an underlying medical condition that can increase chance of having severe COVID-19:  
    • Chronic respiratory disease (including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication)  
    • Chronic heart or vascular disease  
    • Chronic kidney disease  
    • Chronic liver disease  
    • Chronic neurological disease (including dementia, stroke, epilepsy)  
    • Severe and profound learning disability  
    • Down’s syndrome  
    • Diabetes mellitus  
    • Immunosuppression; both primary (e.g. Inherited disorder) or Secondary due to disease or treatment (e.g. sickle cell, HIV, cancer, chemotherapy)  
    • Solid organ, bone marrow, or stem cell transplant recipients  
    • Morbid obesity (BMI >35)  
    • Severe mental illness  
    • Care home resident  
    • Considered by recruiting clinician to be clinically vulnerable 


  1. Half of the participants will receive antivirals and half will not as happens in most trials related to new treatments. This is so the study team can see any difference in the health of those who received the antiviral treatment compared to those who did not.
  2. All participants take part from their own homes, without needing to visit a clinic or hospital. The oral treatment will be delivered directly to their home by the trial team. All participants will still be able to access any health care that they would normally expect to receive.
  3. If you take part in the study, you'll need to complete a daily diary for 28 days. In some areas, you may instead receive a phone call from the trial team on days seven, 14, and 28 to speak about your symptoms while you are in the trial.
  4. Find out more about the University of Oxford COVID-19 antiviral trial on the Panoramic trial website
  5. For media enquiries please contact DoH Press Office by email:  
  6. Follow us on twitter @healthdpt
  7. The Executive Information Service operates an out of hours service for media enquiries only between 1800hrs and 0800hrs Monday to Friday and at weekends and public holidays. The duty press officer can be contacted on 028 9037 8110.

Share this page

Back to top